deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT03943550

Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)

A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics, Preliminary Efficacy, and Pharmacodynamics of Subcutaneously Administered RO7049665 in Participants With Active Ulcerative Colitis

Sponsor: Hoffmann-La Roche

Updated 19 times since 2019 Last updated: Jun 22, 2023 Started: May 13, 2019 Primary completion: Jul 22, 2021 Completion: Jul 22, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The decision to terminate study WP40161 was based on that treatment with RO7049665 showed trends in efficacy, however these data were below expectations and would not have supported superiority over standard of care.

Listed as NCT03943550, this PHASE1 trial focuses on Ulcerative Colitis and remains terminated or withdrawn. Sponsored by Hoffmann-La Roche, it has been updated 19 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jun 2019 – ~Jul 2020 · 13 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Mar 2024 · 27 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

19 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Mar 2024 — Jul 2024 [monthly]

    Terminated PHASE1

  5. Dec 2021 — Mar 2024 [monthly]

    Terminated PHASE1

Show 14 earlier versions
  1. Nov 2021 — Dec 2021 [monthly]

    Terminated PHASE1

    Status: RecruitingTerminated

  2. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE1

  3. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  4. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  5. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  6. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE1

  7. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  8. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  9. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  10. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  11. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE1

  12. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  13. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

  14. Jun 2019 — Jul 2020 [monthly]

    Recruiting PHASE1

    First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .